C4 Therapeutics, Inc. announced the release of further analysis from its fully enrolled Phase 1 trial of cemsidomide, an oral IKZF1/3 degrader, used in combination with dexamethasone for treating relapsed/refractory multiple myeloma. This data will be presented at the European Hematology Association 2026 Congress. C4 Therapeutics, Inc. is a biotechnology company focused on ability-based protein degradation.</div>
